PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-9.79%
Both companies show declining cash positions (-9.79% vs CRVO's -14.28%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-9.79%
Cash + STI yoy 0.5-0.75x CRVO's -14.28%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.77%
0.5-0.75x CRVO's -15.09%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-10.21%
Similar yoy growth to CRVO's -11.29%. Walter Schloss sees parallel capital spending strategies. Check utilization rates.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.10%
≥ 1.5x CRVO's -0.48%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-9.71%
0.75-0.9x CRVO's -11.32%. Bill Ackman questions if competitor invests more aggressively for growth.
3.20%
Similar yoy growth to CRVO's 4.19%. Walter Schloss sees parallel payables strategy. Check top-line correlation.
-75.32%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-4.13%
Both CRVO and the company show zero Deferred Revenue (Current) Growth.
No Data
No Data available this quarter, please select a different quarter.
0.52%
Less than half of CRVO's 50.80%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.45%
Less than half of CRVO's -62.12%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-1.62%
Less than half of CRVO's 2.44%. David Dodd sees far fewer liability expansions relative to competitor.
7.69%
Above 1.5x CRVO's 0.03%. Michael Burry suspects heavy new equity expansion or dilution.
-2.53%
0.5-0.75x CRVO's -4.56%. Martin Whitman is wary of weaker retention or lower profitability.
-4.62%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-10.53%
0.75-0.9x CRVO's -12.63%. Bill Ackman wonders if competitor is growing equity faster.
-9.71%
0.75-0.9x CRVO's -11.32%. Bill Ackman wonders if competitor invests or leverages more aggressively.
No Data
No Data available this quarter, please select a different quarter.
-19.69%
Above 1.5x CRVO's -10.37%. Michael Burry sees a major jump. Investigate leverage rationale.
9.58%
50-75% of CRVO's 14.31%. Bruce Berkowitz notes comparatively lower net debt expansion.